{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:07:52Z","timestamp":1782256072657,"version":"3.54.5"},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Alzheimer's Research & Therapy"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1186\/alzrt63","type":"journal-article","created":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T19:58:19Z","timestamp":1362167899000},"page":"4","source":"Crossref","is-referenced-by-count":14,"title":["Should EOAD patients be included in clinical trials?"],"prefix":"10.1186","volume":"3","author":[{"given":"Kinga","family":"Szigeti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle S","family":"Doody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2016,5,16]],"date-time":"2016-05-16T15:38:39Z","timestamp":1463413119000},"score":1,"resource":{"primary":{"URL":"http:\/\/alzres.biomedcentral.com\/articles\/10.1186\/alzrt63"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1186\/alzrt63","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"print"}],"subject":[],"published":{"date-parts":[[2011]]}}}